Bold claim: Depression and diabetes don’t just coexist — they amplify each other in real and measurable ways. And this is where pharmacists can make a decisive difference by coordinating care that tackles both conditions at once.
Diabetes affects just under 12% of the U.S. population, while depression sits around 9%. Yet the true story lies in the strong, bidirectional link between these conditions. A diagnosis of one increases the likelihood of developing the other, and treatments for one can influence the symptoms or management of the other. Clinicians don’t always recognize this overlap, which can leave patients underserved. Pharmacists, with their specialized knowledge of medications and patient care, are uniquely positioned to bridge this gap and guide both patients and other providers through this complex landscape.
Understanding the connection between diabetes and depression
Chronic illnesses in general raise the risk of depression, driven by the stress and anxiety of long-term management or by side effects of treatments. In diabetes care specifically, the risk is notable: people with diabetes are about twice as likely to develop depression as those without the condition. Depression can mimic some diabetes symptoms, making diagnosis tricky. For example, the M SIG E CAPS framework helps clinicians spot common signs of depression: mood changes, sleep disturbances, loss of interest, guilt, low energy, concentration problems, appetite or weight changes, psychomotor changes, and suicidal thoughts. At least five symptoms are required for a diagnosis, with one being depressed mood or anhedonia. However, many diabetes symptoms—such as sleep disruption, appetite changes, or low energy—can look like depressive symptoms, which can blur the clinical picture.
Medication effects add another layer of complexity. Newer diabetes therapies, including GLP-1 receptor agonists, often promote weight loss, while some patients with depression experience weight loss as well. This intersection can complicate both diagnosis and treatment decisions, particularly when trying to interpret energy levels and motivation. Depression can also sap motivation for exercise, goal setting, or daily self-care tasks like monitoring glucose or administering insulin, which in turn affects diabetes control.
Treatment challenges at the crossroads of depression and diabetes
Antidepressants, a common treatment for depression, come with potential side effects that may worsen diabetes management. Many antidepressants carry varying risks of weight gain or appetite changes, which can influence glucose levels and overall metabolic control. Some evidence indicates that long-term antidepressant use is linked with higher diabetes risk, though such medications may also reduce mortality in people with type 2 diabetes in certain contexts.
Comorbidity often includes substance use disorders, further complicating treatment. Antipsychotics, for instance, can adversely affect glucose metabolism, so clinicians routinely check glucose levels when these medications are prescribed. Some antidepressants, including selective serotonin reuptake inhibitors (SSRIs), may impact pancreatic function or insulin release, and hypoglycemia has been reported when SSRIs are used with sulfonylureas.
The pharmacist’s role in integrated care
A patient-centered approach is essential for anyone managing diabetes or depression, or both. Pharmacists should screen for the other condition when one is present and closely monitor how medications affect both health outcomes and quality of life. Real-world examples include patients who struggle with GLP-1 therapies due to mood-related side effects or those who respond positively to weight-neutral strategies that still address mood symptoms.
A collaborative approach across specialties is crucial. When antipsychotics are used, weight management strategies like GLP-1 agonists may be considered to offset potential weight gain. It’s important to have an open discussion with patients about risks and benefits to align treatment with their preferences and goals. In practice, engaging patients in decision-making leads to better adherence and more meaningful outcomes.
Key takeaways for practice
- Screen regularly for depression in patients with diabetes, and assess diabetes symptoms in patients with depression. This helps catch overlap early and tailor interventions.
- Be mindful of medication interactions and how treatments for one condition might influence the other, including weight changes, appetite, energy, and glucose control.
- Emphasize a truly patient-centered plan that involves education, shared decision-making, and ongoing monitoring of mood, activity levels, and glycemic metrics.
- Foster cross-disciplinary collaboration among prescribers to break down silos and coordinate care. Shared goals across specialties typically yield the best outcomes for both mental and metabolic health.
Controversial notes and questions for readers
- Some clinicians argue that antidepressants may worsen metabolic health for certain patients, while others point to the potential for mood stabilization to improve diabetes self-management. Which perspective aligns with your experience, and why? Could there be patient subgroups for whom one approach is clearly superior?
- The role of weight change in choosing diabetes therapies or antidepressants can be controversial. Should weight-neutral or weight-stable regimens take priority even if they come with other trade-offs? How should patient values drive these decisions?
References and further reading
- Vest K, Grady SE. Managing the Highs and Lows of Co-Morbid Depression and Diabetes. American Society of Health-systems Pharmacists Midyear 2025 Clinical Meeting and Exposition. December 7-10, 2025. Las Vegas, Nevada.
- National Institute of Mental Health. Chronic Illness and Mental Health: Recognizing and Treating Depression. National Institute of Mental Health. Published 2024. https://www.nimh.nih.gov/health/publications/chronic-illness-mental-health
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
